Physician profile
Nasrin Ejtemaee
NPI 1497850077
$3,437.90
in general payments reported to CMS, 2019-2025
23 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $209 · 2021: $658 · 2022: $608 · 2023: $703 · 2024: $645 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.55 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $652.44 | 2020-2025 | |
| Glaxosmithkline, LLC. | $414.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $296.34 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $227.63 | 2019-2025 | |
| Lilly USA, LLC | $218.64 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $170.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.14 | 2019-2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $98.95 | 2022-2023 | Qelbree |
| Astellas Pharma US INC | $79.45 | 2022-2025 | Veozah |
| Amgen INC. | $74.53 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $47.83 | 2024 | |
| Genentech USA, INC. | $37.54 | 2020-2021 | |
| Shire North American Group INC | $36.54 | 2019 | |
| Amarin Pharma, INC. | $35.99 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.32 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Hologic Sales and Service, LLC | $16.84 | 2021 | |
| Currax Pharmaceuticals LLC | $16.28 | 2024 | Contrave |
| Esperion Therapeutics, INC. | $14.53 | 2021 | |
| Mayne Pharma Commercial LLC | $14.35 | 2021 | |
| Merck Sharp & Dohme LLC | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasrin Ejtemaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.